Doi.org/10.1002/cncr.10307
Jump to navigation
Jump to search
Target Article[edit | edit source]
High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study ; Thomas M Behr Frank Griesinger Joachim Riggert Stefan Gratz Martin Béhé Cornelia C Kaufmann Be; NULL; 02/12/2002; https://doi.org/10.1002/cncr.10307
Reasons[edit | edit source]
Note: Reasons not yet here included, but you are welcome to insert this information whenever you wish.